Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC lessened its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 85.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,683 shares of the company’s stock after selling 101,055 shares during the quarter. ADAR1 Capital Management LLC’s holdings in Dianthus Therapeutics were worth $385,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in Dianthus Therapeutics during the 3rd quarter worth approximately $556,000. Barclays PLC grew its stake in shares of Dianthus Therapeutics by 390.5% in the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after acquiring an additional 33,185 shares during the last quarter. State Street Corp increased its holdings in shares of Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after purchasing an additional 413,425 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after purchasing an additional 97,362 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Dianthus Therapeutics in the third quarter valued at approximately $1,473,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Trading Down 5.0 %

Shares of NASDAQ DNTH opened at $16.12 on Monday. The firm has a fifty day simple moving average of $21.48 and a two-hundred day simple moving average of $23.89. The firm has a market capitalization of $517.86 million, a PE ratio of -6.45 and a beta of 1.62. Dianthus Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on DNTH. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, TD Cowen began coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $54.33.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.